Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Kyowa Kirin’s KRN23 Gets BT Designation for X-Linked Hypophosphatemia in Children
June 30, 2016
- Novel Anti-HIV Agent Genvoya to Hit Japan Market on July 8: JT, Torii
June 30, 2016
- Celgene Files Revlimid for ATL in Japan
June 30, 2016
- Reconsider Appropriate Diabetes Drug Combos Including GLP-1 Agents: Diabetologist
June 29, 2016
- MSD Initiates Long-Term Observational Study of Treatment with Oral Hypoglycemic Agents
June 29, 2016
- Boehringer-Sanofi Asset Swap Slated to Close by Year’s End; Fate of Japan Units Subject to Future Discussions
June 28, 2016
- Daiichi Sankyo, Servier Sign Sales Accord for Edoxaban in Canada
June 28, 2016
- Takeda Returns Japan Rights for Some Amgen Products
June 27, 2016
- Teijin Pharma Will Block Feburic Generic Erosions by Expanding Indications: President
June 24, 2016
- Cellular Dynamics, US National Eye Institute Ink Pact to Advance Cell Transplantation Therapy for AMD
June 24, 2016
- Univ. of Tokyo, Astellas to Codevelop Rice-Based Oral Cholera Vaccine
June 24, 2016
- Sanofi’s Antibody Drug for Atopic Dermatitis Close to Regulatory Filing
June 23, 2016
- Asahi Kasei Inks Collaboration with Finland’s Orion on Pain Therapies
June 23, 2016
- Interview: Bayer Yakuhin Chief Spearheading Initiatives to Trigger Behavior Change in Employees
June 23, 2016
- Fujifilm Inks 1st License Deal for Avigan Patents with Chinese Pharma
June 23, 2016
- Takeda to Partner with US NPO for Joint Program to Explore Lead Compounds for TB Therapies
June 23, 2016
- Bayer Japan Revs Up Drive to Spark Behavior Change, Offers Patient Insights to Back Office Staffers
June 22, 2016
- Takao Hayakawa Tapped as New Chief of Kaketsuken
June 22, 2016
- Takeda Kicks Off PIIb Trial for Norovirus Vaccine in US
June 22, 2016
- AnGes MG Alters Global Collategene Strategy, Initial Focus Now on US
June 21, 2016
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…